199.90EUR-2.11%Mkt Cap: 29.07B $P/E: 40.301d ago
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for h…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap29.07B $
Enterprise Value28.30B $
Revenue (TTM)5.22B $
Gross Profit3.30B $
Net Income (TTM)341.03M $
Revenue/Share39.40 USD
Last Price199.90 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINUS02043Q1076
Valuation
P/E (Trailing)40.30
P/E (Forward)—
PEG0.43
EV/EBITDA24.69
EV/Revenue5.42
P/S5.49
P/B22.51
EPS (TTM)4.97
EPS (Forward)—
52W Range
196.9533% of range205.80
52W High205.80 EUR
52W Low196.95 EUR
Profitability
Gross Margin81.64%
Oper. Margin17.93%
EBITDA Margin21.95%
Profit Margin8.45%
ROE39.76%
ROA6.32%
Growth
Revenue Growth66.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF569.65M $
CapEx (TTM)63.80M $
FCF Margin5.65%
FCF Yield1.02%
Net Debt-348.54M $
Net Debt/EBITDA-0.30
Balance Sheet
Debt/Equity1.62
Current Ratio3.06
Quick Ratio2.79
Book Value/Sh8.749 EUR
Cash/Share24.72 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.133.81M
Float133.24M
Insiders0.18%
Institutions101.68%
Technical
SMA 50238.31 (-16.1%)
SMA 200285.81 (-30.1%)
Beta0.28
S&P 52W Chg20.80%
Avg Vol (30d)57
Avg Vol (10d)138
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—